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Background: The pleiotropic hormone H2 relaxin can bind to both RXFP1 and RXFP2 receptors.
Results: A-chain-modified H2 relaxin analogues retain RXFP1 activity and anti-fibrotic properties while ablating RXFP2
responses.
Conclusion:Residues withinH2 relaxin A-chain play a prominent role inmaintaining structural fold and directing the receptor
specificity.
Significance: We identified A-chain residues critical for receptor-ligand interactions, useful for development of future
therapeutics.
Human gene-2 (H2) relaxin is currently in Phase III clinical
trials for the treatment of acute heart failure. It is a 53-amino
acid insulin-like peptide comprising two chains and three disul-
fide bonds. It interacts with two of the relaxin family peptide
(RXFP) receptors. Although its cognate receptor is RXFP1, it is
also able to cross-react with RXFP2, the native receptor for a
related peptide, insulin-like peptide 3. In order to understand
the basis of this cross-reactivity, it is important to elucidate both
binding and activationmechanisms of this peptide. The primary
binding mechanism of this hormone has been extensively stud-
ied andwell defined.H2 relaxin binds to the leucine-rich repeats
of RXFP1 andRXFP2 using B-chain-specific residues. However,
little is known about the secondary interaction that involves the
A-chain of H2 relaxin and transmembrane exoloops of the
receptors. We demonstrate here through extensive mutation of
the A-chain that the secondary interaction between H2 relaxin
and RXFP1 is not driven by any single amino acid, although
residues Tyr-3, Leu-20, and Phe-23 appear to contribute. Inter-
estingly, these same three residues are important drivers of the
affinity and activity of H2 relaxin for RXFP2 with additional
minor contributions from Lys-9, His-12, Lys-17, Arg-18, and
Arg-22. Our results provide new insights into themechanism of
secondary activation interaction of RXFP1 and RXFP2 by H2
relaxin, leading to a potent and RXFP1-selective analog,
H2:A(4–24)(F23A), which was tested in vitro and in vivo and
found to significantly inhibit collagen deposition similar to
native H2 relaxin.
Human gene-2 (H2)7 relaxin, the major stored and circulat-
ing form of human relaxin, is a 53-amino acid peptide hormone
that has structural characteristics common to the insulin/re-
laxin family members, namely two peptide chains stabilized by
three disulfide bonds (1, 2). In most mammals, relaxin has long
been regarded as a hormone of pregnancy and is involved in
remodeling the connective tissue of the pelvic ligaments and
female reproductive tract to facilitate delivery of the young.
However, relaxin is a pleiotropic hormonewith additional roles
in several non-reproductive processes that are centered around
its anti-fibrotic (3), vasodilatory, and cardioprotective effects
(4). Based on the latter two actions, human H2 relaxin is cur-
rently in Phase III clinical trials for the treatment of patients
with acute heart failure (5).
H2 relaxin interacts with G protein-coupled receptors,
recently renamed relaxin family peptide receptors (RXFP).
Although the native receptor for H2 relaxin is RXFP1 (6), it also
strongly binds to and activates RXFP2, the native receptor for
related peptide insulin-like peptide 3 (INSL3) (7). Both RXFP1
and -2 receptors are class C leucine-rich repeat (LRR)-contain-
ing G protein-coupled receptors. The large extracellular
domain of these receptors consists of series of LRR strands
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forming a parallel -sheet linked to a low density lipoprotein
receptor type A module (8).
The receptors RXFP1 and -2 are currently known to possess
high and low affinity binding sites (also referred to as primary
and secondary interaction sites) by which they interact with
their ligands (9, 10). The primary mode of ligand-receptor
interaction has been extensively studied andwell characterized.
The binding cassette (RXXXRXXI) present within the mid-re-
gion of the B-chain is responsible for the primary binding inter-
action of H2 relaxin with the LRR of its native receptor RXFP1
(11). The corresponding residues in RXFP1 interactingwith the
B-chain binding motif were later identified by mutations of the
LRR region of the receptor (12). A pair of acidic residues (Asp
and Glu) within RXFP1 form hydrogen bonds with each con-
served residue (Arg) of the B-chain, whereas the single isoleu-
cine residue forms hydrophobic interactions with the corre-
sponding hydrophobic cluster (Trp, Ile, and Leu) present in the
inner sheets of the LRR. Similar to the interaction of H2 relaxin
with RXFP1, residues, such as His-12, Arg-16, Val-19, Arg-20,
and Trp-27, present within the INSL3 B-chain are responsible
for its high affinity binding to the LRR of RXFP2 (13). The
corresponding residues in RXFP2 interacting with the B-chain
of INSL3were also determined andwell characterized by recep-
tor mutation studies (14). The INSL3-RXFP2 interaction site is
different to the site of relaxin-RXFP1 interaction. Interestingly,
when H2 relaxin binds to and activates RXFP2 receptor, it uti-
lizes a hybrid relaxin/INSL3 binding site consisting partly of the
INSL3-RXFP2 and H2 relaxin-RXFP1 interactions (15).
The recent evidence strongly suggest that there is a second-
ary interaction between ligands (H2 relaxin and INSL3) and
receptors (RXFP1 and RXFP2), which ultimately causes activa-
tion and downstream signaling. It is now believed that such
interactions involve the A-chain of ligands and the transmem-
brane (TM) exoloops of the receptors (16). The studies involv-
ing chimeric peptides and receptors have provided some
insights into the mechanism of secondary interaction between
peptides and receptors. For example, the nativeH3 relaxin pep-
tide, anothermember of the insulin/relaxin family that is a neu-
ropeptide, strongly binds to and activates its cognate RXFP3
receptor but also RXFP1. However, the chimeric peptide R3/I5,
where the A-chain of H3 relaxin was replaced with the INSL5
A-chain, displayed no activity at RXFP1 while maintaining full
activation at RXFP3, indicating that H3 relaxin binds to and
activates its native receptor (RXFP3) using B-chain-specific
residues, whereas it requires both the A- and B-chains to inter-
act with the RXFP1 receptor (17). This result is supported by
the facts that a single H3 relaxin B-chain can act as an RXFP3
agonist (17, 18) and a modified single B-chain can act as an
antagonist (19). The importance of the H3 relaxin A-chain for
RXFP1 activity is further supported by the fact thatH3 relaxin is
unable to activate a chimeric receptor comprising the LRR from
RXFP1 and TM exoloops from RXFP2 (9). The other chimeric
peptides recently studied, H2A-INSL3B (20) and INSL3A-H2B
(21), exhibited poor or partial activity at RXFP2. This was sur-
prising, given the fact that both INSL3 andH2 relaxin are strong
RXFP2 agonists. Interestingly, when the chimeric peptide
H2A-INSL3B was tested against an RXFP2 chimeric receptor
comprising of the TM domain from RXFP1, full activation of
the receptor was observed. These results highlight that the
A-chains of H2 relaxin and INSL3 play a key role in interacting
with the TM exoloops of RXFP1 or RXFP2, and the mode by
which H2 relaxin or INSL3 binds to the LRR of RXFP2 is not
compatible with the interaction between the A-chain of these
chimeric peptides and TM exoloops of RXFP2 (21).
Recently, the residues and domains in the INSL3 A-chain
that are involved in secondary interactions with RXFP2 have
been decoded (20). No single amino acid within the INSL3
A-chain was found to be critical for RXFP2 activity. However,
the N terminus domain consisting of 5 residues was identified
to be crucial for activation and not for binding. This provides an
explanation of why truncations at the N terminus of INSL3
produced a high affinity RXFP2 antagonist (22). Unlike the
INSL3-RXFP2 system, the secondary interactions in both
H2-RXFP1 and H2-RXFP2 systems are less well characterized,
and the residues involved in these interactions have not
been fully determined. Therefore, we performed mutations
and/or truncations of the H2 relaxin A-chain in this study in
order to identify the key determinants required for second-
ary interaction.
We demonstrate here that the secondary interaction
between H2 relaxin and RXFP1 is not driven by any individual
amino acid in the A-chain. This led to the assembly of H2
relaxin A-chain partial chimeras with INSL5 domains to pro-
vide a better understanding of which residues or domains that
may be crucial for RXFP1 binding and activation. Last, N ter-
minus truncations and/or single amino acid mutations of the
H2 relaxin A-chain were carried out that led to the identifica-
tion of RXFP1-selective H2 relaxin analogues in parallel to
determining the amino acid residues present in the A-chain
that are responsible for native folding and thus conferring
receptor selectivity. This study offers important insights into
the secondary interactions between H2 relaxin and RXFP1 or
RXFP2.
EXPERIMENTAL PROCEDURES
Solid-phase Peptide Synthesis
Individual A- and B-chains of H2 relaxin analogues with
appropriate regioselective S-protection were synthesized
using either continuous flow or microwave-assisted solid-
phase methodologies on an automated PerSeptives Biosys-
tems Pioneer peptide synthesizer and a CEM Liberty peptide
synthesizer, respectively. Following simultaneous cleavage,
side chain deprotection, and purification of crude A- and
B-chains, stepwise formation of the three disulfide bonds
were carried out via oxidation, thiolysis and iodolysis con-
secutively (23–26). Altogether, there were 16 H2 relaxin ana-
logues synthesized in this study, 10 of which were A-chain
alanine-substituted (A3 (Tyr 3 Ala), A9 (Lys 3 Ala), A12
(His3 Ala), A16 (Thr3 Ala), A17 (Lys3 Ala), A18 (Arg3
Ala), A19 (Ser 3 Ala), A20 (Leu 3 Ala), A22 (Arg 3 Ala),
and A23 (Phe 3 Ala)) and three H2 relaxin analogues with
amino acid substitutions and/or truncations (A(4–24), A(4–
24)(Phe 3 Ala), and A(4–23)(F)). In addition, three
H2/INSL5 chimeric analogues with three different domains
were prepared. All native H2 relaxin and its analogues com-
Key Residues Identified within H2 Relaxin A-chain
NOVEMBER 30, 2012•VOLUME 287•NUMBER 49 JOURNAL OF BIOLOGICAL CHEMISTRY 41153
 at UQ Library on September 1, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
prised two chains (A- and B-chains) linked covalently by
three disulfide bonds.
Peptide Characterization
The purity of individual synthetic peptides was assessed by
analytical reversed-phase high performance liquid chromatog-
raphy using a Vydac C18 column (250 4.6 mm, 300 Å, 5 m)
with a buffer system of 0.1% trifluoroacetic acid in water (buffer
A) and 0.1% trifluoroacetic acid in acetonitrile (buffer B). The
molecular weights of all analogues were determined by
MALDI-TOF mass spectrometry using a Bruker AutoflexII
instrument (Bremen, Germany) in the linear mode at 19.5 kV.
Furthermore, the peptide content was quantitated by amino
acid analysis using vapor-phase acid hydrolysis in 6 M hydro-
chloric acid containing 2% phenol at 110 °C over 24 h. The
hydrolysate was then converted to stable, fluorescent deriva-
tives using a Waters AccQTag kit (Sydney, Australia). The
derivatized amino acids were separated using a Shim-Pak XR
ODS column (3  75 mm, 2.2 m) on a Shimadzu microbore
reversed-phase HPLC system (Victoria, Australia).
Circular Dichroism (CD) Spectroscopy
CD spectra were obtained using a JASCO spectrophotome-
ter (J-185) (JASCO, Tokyo, Japan) at 25 °C in a 1-mm path
length cell. The peptides were dissolved at a concentration of
0.2 mg/ml in 10 mM phosphate buffer (pH 7.5).
NMR Structural Analysis
H2:A(Y3A) and H2:A(4–24)(F23A) were analyzed by solu-
tion NMR spectroscopy. Samples prepared comprised 1 mg
of either H2:A(Y3A) or H2:A(4–24)(F23A) dissolved in 0.5 ml
of 90% H2O, 10% D2O at pH 4. Two-dimensional homo-
nuclear experiments, including TOCSY and NOESY, with a
mixing time of 150 ms were recorded at 600 MHz using a
Bruker Avance spectrometer. Additional two-dimensional
experiments for H2:A(Y3A) were recorded at 900 MHz on a
Bruker Avance II equipped with a cryogenic probe. Data sets
were generally recorded with 4000 complex data points in the
direct dimension and 512 increments in the indirect dimension,
with the latter zero-filled to the 1000 data point, and both
dimensions were multiplied by a sine square function prior to
transformation. All data were recorded and processed using
TOPSPIN 3.0 (Bruker) and analyzed using CARA (27). Data
were referenced using the residual water signal at 4.77 ppm.
Ligand Binding Assay
Human embryonic kidney (HEK-293T) cells stably trans-
fected with RXFP1 or RXFP2 were cultured in RPMI 1640
medium (Sigma) supplemented with 10% fetal calf serum, 100
g/ml penicillin, 100 g/ml streptomycin, and 2 mM L-gluta-
mine and plated into 96-well plates precoated with poly-L-ly-
sine for whole cell binding assays. Competition binding exper-
iments were conducted with either europium-labeled H2
relaxin (28) or europium-labeled INSL3 (29) in the absence or
presence of increasing concentrations of unlabeled H2 relaxin
peptide analogues. Nonspecific binding was determined with
an excess of unlabeled peptides (500 nM H2 relaxin or INSL3).
Fluorescent measurements were recorded at an excitation
wavelength of 340 nm and emission of 614 nm on a Victor plate
reader (PerkinElmer Life Sciences). All data were are presented
as themean S.E. of the percentage of the total specific binding
of triplicate wells, repeated in at least three separate experi-
ments, and curves were fitted using one-site binding curves in
GraphPad Prism 4 (GraphPad Inc, San Diego, CA). Statistical
differences in pIC50 values were analyzed using one-way anal-
ysis of variance coupled to the Newman-Keuls multiple com-
parison test for multiple-group comparisons in GraphPad
Prism 4.
Functional cAMP Assay
The ability ofH2 relaxin and its analogues to stimulate cAMP
response was evaluated using a cAMP reporter gene assay as
described previously (10). HEK-293T cells co-transfected with
either RXFP1 or RXFP2 and a pCRE -galactosidase reporter
plasmid were plated in 96-well plates (30). After 24 h, the co-
transfected cells were incubated with increasing concentra-
tions of H2 relaxin analogues in parallel to 10 nM H2 relaxin or
INSL3 for RXFP1- or RXFP2-transfected cells, respectively.
The amount of cAMP-driven -galactosidase expression in
each well was assessed with a colorimetric assay measuring
absorbance at 570 nm on a Benchmark Plus microplate spec-
trophotometer (Bio-Rad). Ligand-induced cAMP stimulation
was expressed as a percentage of maximal response of H2
relaxin or INSL3 for RXFP1 and RXFP2 cells, respectively. Each
data point wasmeasured in triplicate, and each experiment was
conducted independently at least three separate times. Statisti-
cal differences in pEC50 values were analyzed using one-way
analysis of variance coupled to the Newman-Keuls multiple
comparison test for multiple group comparisons in GraphPad
Prism 4.
Determination of Collagen Content
In Vitro Studies—Based on the ability of native H2 relaxin to
inhibit TGF-1-stimulated aberrant collagen deposition when
applied to various types of fibroblasts (31–33) via RXFP1, the
efficacy of the H2:A(4–24)(F23A) analog was compared with
that of H2 relaxin via measurement of collagen deposition in
BJ3 cells, a human dermal fibroblast cell line (34) that endoge-
nously expresses RXFP1. BJ3 cells were maintained and plated
for experimentation as detailed previously (35). TGF-1 (2
ng/ml)-stimulated cells were treated for 72 h with either native
H2 relaxin (100 ng/ml; 16.8 nM) or an equivalent concentration
of the H2:A(4–24)(F23A) analog (16.8 nM), whereas TGF-1-
unstimulated cells treated with or without the H2:A(4–
24)(F23A) analog were used as appropriate controls (from
which basal collagen deposition could bemeasured). These treat-
mentswere carried out three or four separate times in duplicate or
triplicate. The amount of collagen deposited by BJ3 cells into the
matrix was then determined, as described before (35).
In Vivo Studies—Because H2 relaxin has consistently been
found to prevent and/or reverse fibrosis progression in numer-
ousmousemodels of disease (throughRXFP1 alone), regardless
of etiology (3, 4, 32, 36), the efficacy of the H2:A(4–24)(F23A)
analog was also compared with that of H2 relaxin via measure-
ment of collagen deposition (fibrosis) in an isoproterenol
(ISO)-induced murine model of myocardial injury (37). Briefly,
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8–10-week-old male mice on a C57B6J  129SV background
(n 15)were subcutaneously injectedwith isoprenaline hydro-
chloride (25 mg/kg; Sigma-Aldrich) once daily for 5 consecu-
tive days and then left for a further 12 days for fibrosis progres-
sion to occur. Subgroups of animals (n  5/group) received
recombinant H2 relaxin (0.5 mg/mg/day; a dose that has been
used previously to successful demonstrate its anti-fibrotic
actions (3, 32, 36) and produces circulating levels of 20–40
ng/ml (38), which are well within those found in pregnant
rodents). Alternatively, an equivalent dose of the H2:A(4–
24)(F23A) analog (0.5 mg/kg/day) was administered via subcu-
taneously implanted osmotic minipumps (model 2002; Alzet,
Cupertino, CA), which allowed for the continuous infusion of
each peptide into the circulation of treated animals. A separate
subgroup of mice (n  5) that were not subjected to ISO or
peptide treatmentwere used as untreated controls. Twelve days
after the fifth ISO injection/17 days from the beginning of the
study, all mice were weighed and then sacrificed for heart and
left ventricular collection.
A similar portion of the left ventricle from each animal was
then used for the determination of hydroxyproline content, as
described before (39). Hydroxyproline values were then con-
verted to collagen content as detailed previously (35, 39) and, in
turn, divided by the dry weight of each corresponding left ven-
tricular tissue assessed to yield collagen concentration (a meas-
ure of fibrosis).
RESULTS
Design and Synthesis of H2 Relaxin Analogues
A series of H2 relaxin analogues were designed and synthe-
sized in this study (Table 1) in order to identify key residues
involved in secondary interaction.Ourwell established regiose-
lective disulfide formation chemical approach was utilized to
assemble these two-chain peptides where three differential cys-
teine S-protecting groups (Trt, tBu, and Acm) were used to
assist the direct formation of the three disulfide bonds. The
successful formations of the peptides were achieved in good
overall yields (10–14% relative to starting B-chain material)
and were subjected to comprehensive characterization by
MALDI-TOF mass spectrometry and reversed-phase HPLC,
which confirmed their high purities.
Effects of Single Alanine Substitutions of H2 Relaxin A-chain
on RXFP1 and RXFP2
The importance of the A-chain structure and the specific
contributions of individual amino acid residues within the
A-chain toward receptor binding and activation were investi-
gated by the preparation of H2 relaxin analogues that had indi-
vidual amino acids within their A-chains replaced with alanine
(Table 1). Cell-based assays were used to evaluate the ability of
these analogues to bind and signal through RXFP1 and RXFP2
(Table 2). The single alanine substitutions within most of the
A-chain analogues were found to retain similar affinity to that
of native H2 relaxin for RXFP1. The corresponding activation
response of these analogues correlated with the binding data
suggesting that the side chains of these individual native resi-
dues donot greatly affect binding and activation at RXFP1 (Figs.
1 and 2). However, three H2 relaxin analogues, H2:A(Y3A),
H2:A(L20A), and H2:A(F23A), displayed a decrease in affinity
and potency for RXFP1 (Fig. 1 and Table 2). At RXFP2, most of
the analogues displayed reduced binding affinity and potency
(Fig. 2 and Table 2) compared with native H2 relaxin. Interest-
ingly, H2:A(Y3A), H2:A(L20A), and H2:A(F23A) bound with
remarkably lower affinity at RXFP2 and with correspondingly
reduced activation response at RXFP2 (Fig. 2 and Table 2). This
indicates that Tyr-3 at the N terminus and Leu-20 and Phe-23
at the C terminus of the A-chain are key residues for RXFP2
binding and activation.
Effects of Truncationwith/without Single Alanine
Substitutions of H2 Relaxin A-chain on RXFP1 and RXFP2
We have recently designed and created a truncated relaxin
analog, H2:(A4–24)(B7–24), having an active core of 38 amino
acids that displayed high RXFP1 selectivity over RXFP2 (35).
Because of the numerous truncations, it was unclear which spe-
cific residue(s) contributed to the complete loss of RXFP2 activ-
ity, although Trp-28 is believed to be one of them (14, 35). The
alanine scanning results described above now suggest that
Tyr-3 in the A-chain is another important residue for RXFP2
activity. This observation is also supported by anA-chain short-
ened analog H2:A(5–24), which exhibited full RXFP1 affinity
and significantly reduced affinity at RXFP2 (40). Hence, we
hypothesized that truncation of the first few residues, including
Tyr-3 of the A-chain together with a single alanine substitution
at Phe-23, could aid in retaining close to native RXFP1 affinity
while completely abolishing RXFP2 actions. Therefore, we first
synthesized H2:A(4–24) as a control to confirm if this peptide
is fully active at RXFP1, followed by our target analog H2:A(4–
24)(F23A) (Table 1). We showed that both analogues retained
almost similar binding and cAMP responses to native H2
relaxin at RXFP1 (Fig. 3 and Table 2) but were able to signifi-
cantly reduce binding and activation at RXFP2 (Fig. 4 andTable
2). This series of analogues further confirmed the importance of
theN- andC termini regions of the A-chain in directing RXFP2
specificity. To further prove our hypothesis that bothTyr-3 and
Phe-23 are key residues for RXFP2 activity, we prepared
another analog, H2:A(4–24)F23, by removing both Tyr-3 and
Phe-23 (Table 1) from the A-chain. It was found that H2:A(4–
24)F23 was able to completely abolish RXFP2 binding and
cAMP responses but the responses at RXFP1 were compro-
mised with a 1.5-fold log unit decreased shift in binding capac-
ity (Fig. 4 and Table 2).
Effects of Chimeric H2/INSL5 A-chains on RXFP1 and RXFP2
Chimeric H2 relaxin analogues were designed and synthe-
sized (Table 1) to introduce the INSL5 A-chain in three differ-
ent domains within the native H2 relaxin A-chain that were
linked to native H2 relaxin B-chain. This was done in order to
study the role of native H2 relaxin A-chain with different
domains because no single amino acid was found to be very
critical for RXFP1 action. Using such a strategy, we have
recently identified a domain of 5–9 residues at the N terminus
of the INSL3 A-chain that is critical for RXFP2 activation (20).
In this study, three partial chimeric peptides were successfully
prepared and tested. Chimera 1 had the first 9 residues replaced
with the first 6 residues of the INSL5 A-chain; chimera 2 had
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the middle 3 residues present between the 2 cysteine residues
replaced; and last, chimera 3 had the C-terminal region of
native H2 relaxin swapped with INSL5 (Table 1). Functional
studies showed that chimeras 1 and 3 resulted in a significant
loss of binding and activation at bothRXFP1 (Fig. 5 andTable 2)
and RXFP2 (Fig. 6 and Table 2), whereas chimera 2 was able to
retain some native affinity and potency at RXFP1 (Fig. 5A). This
could be due to the fact that the nativeA-chain domain replace-
ments with INSL5 A-chain residues led to the disruption of the
native structure, thus resulting in poor affinity and potency at
RXFP1 because of its inability to bind to the receptor in the
proper conformation. In addition, the INSL5 A-chain is not a
natural ligand for either RXFP1 or RXFP2. This explains the
hypothesis that although single alanine substitutions did not
cause a dramatic effect on binding and activation, it is impor-
tant to have native A-chain residues at both the N- and C-ter-
minal domains to retain the structure that is essential for effec-
tive ligand-receptor interactions.
Structural Studies of H2 Relaxin Analogues
To understand the influence of A-chain mutation on the
conformation of H2 relaxin peptides, CD spectroscopy was
employed for both native H2 relaxin and one of the mutated
analogues, H2:A(Y3A). The CD spectra of both native and ana-
log peptides revealed a typical -helical pattern with double
minima at 208 and 222 nm.Themean residual weight ellipticity
TABLE 1
Amino acid sequences of native H2 relaxin and 16 analogues with both A- and B- chains linked by one intra- and two interdisulfide bonds were
designed and prepared for this study
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values at 222 nm, []222, were used to determine the helix con-
tent of the peptides. The []222 value for native H2 relaxin is
15,056.9 and corresponds to an -helix content of 42%. A
single amino acid substitution at theN terminus of theA-chain,
H2:A(Y3A), resulted in a decrease of the []222 value,
11,283.5, corresponding to 32% helicity content (Fig. 7A).
To further confirm the effect of the mutations on overall
structure, two of the analogues with altered pharmacological
TABLE 2
Competition binding (pKi) and activation (pEC50) of RXFP1 and RXFP2 by H2 relaxin and analogues
a p 0.001 versus H2 relaxin.
b p 0.01 versus H2 relaxin.
c p 0.05 versus H2 relaxin.
d NA, no activity.
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profile, H2:A(Y3A) and H2:A(4–24)(F23A), were analyzed by
solution NMR spectroscopy. The H2:A(4–24)(F23A) variant
showed in comparison with native H2 relaxin significantly
poorer signal dispersion and generally broad lines, suggesting a
rather compromised overall fold not amenable to resonance
assignments. In contrast, the H2:A(Y3A) variant showed good
resonance dispersion, consistent with an ordered structure in
solution, albeit with somewhat broader lines than native H2
relaxin. Nonetheless, using ultra-high field two-dimensional
NMRdata recorded at 900MHzusing a cryoprobe, nearly com-
plete resonance assignments of the peptide backbone andmost
side chain resonances could be achieved through standard
FIGURE 1. Activity of H2 analogues with single alanine mutations on the RXFP1 receptor. A, competition binding results of native H2 relaxin and single
alanine-mutated H2 analogues (N terminus to mid-region of the A-chain) in the presence of a competitive ligand Eu3-labeled H2 relaxin tested in HEK-293T
cells stably expressing RXFP1 receptors. Data are expressed as a percentage of specific binding and are pooled data fromat least three experiments performed
in triplicate. B, cAMP activity of native H2 relaxin and single alanine-mutated H2 analogues (N terminus to mid-region of the A-chain) in HEK-293T cells
expressing RXFP1 receptors using a pCRE-galactosidase reporter gene system. Data are expressed as a percentage of maximum H2 relaxin-stimulated cAMP
response and are pooled data from at least three experiments performed in triplicate. C, competition binding results of native H2 relaxin and single alanine-
mutatedH2analogues (mid-region toC terminusof theA-chain) in thepresenceof a competitive ligandEu3-labeledH2 relaxin tested inHEK-293T cells stably
expressingRXFP1 receptors.Data are expressedas apercentageof specific bindingandarepooleddata fromat least threeexperimentsperformed in triplicate.
D, cAMP activity of native H2 relaxin and single alanine-mutated H2 analogues (mid-region to C terminus of the A-chain) in HEK-293T cells expressing RXFP1
receptors using a pCRE-galactosidase reporter gene system. Data are expressed as a percentage of maximum H2 relaxin-stimulated cAMP response and are
pooled data from at least three experiments performed in triplicate. Error bars, S.E.
FIGURE 2. Activity of H2 analogues with single alanine mutations on the RXFP2 receptor. A, competition binding results of native H2 relaxin and single
alanine-mutated H2 analogues (N terminus tomid-region of the A-chain) in the presence of a competitive ligand Eu3-labeled INSL3 tested in HEK-293T cells
stably expressing RXFP2 receptors. Data are expressed as a percentage of specific binding and are pooled data from at least three experiments performed in
triplicate. B, cAMPactivity of nativeH2 relaxin and single alanine-mutatedH2 analogues (N terminus tomid-regionof theA-chain) inHEK-293T cells expressing
RXFP2 receptors using a pCRE-galactosidase reporter gene system. Data are expressed as a percentage ofmaximum INSL3-stimulated cAMP response and are
pooled data from at least three experiments performed in triplicate. C, competition binding results of native H2 relaxin and single alanine-mutated H2
analogues (mid-region to C terminus of the A-chain) in the presence of a competitive ligand Eu3-labeled INSL3 tested in HEK-293T cells stably expressing
RXFP2 receptors. Data are expressed as a percentage of specific binding and are pooled data from at least three experiments performed in triplicate.D, cAMP
activity of native H2 relaxin and single alanine-mutated H2 analogues (mid-region to C terminus of the A-chain) in HEK-293T cells expressing RXFP2 receptors
using apCRE-galactosidase reporter gene system.Data are expressed as apercentageofmaximum INSL3-stimulated cAMP response andarepooleddata from
at least three experiments performed in triplicate. Error bars, S.E.
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homonuclear sequential assignment strategies (41). Secondary
H shifts (i.e. differences between observed chemical shifts and
the chemical shifts expected for corresponding amino acids in
random coil type structure) are sensitive indicators of second-
ary structure (42). The secondary shifts for H2:A(Y3A) are
reported in Fig. 7B and compared with corresponding values
FIGURE 3.Activity of H2 analogues with truncations and/or single alaninemutation on the RXFP1 receptor. A, competition binding results of native H2
relaxin and H2 analogues with truncation and/or single alanine mutation in the presence of a competitive ligand Eu3-labeled H2 relaxin tested in HEK-293T
cells stably expressing RXFP1 receptors. Data are expressed as a percentage of specific binding and are pooled data fromat least three experiments performed
in triplicate. B, cAMP activity of native H2 relaxin and H2 analogues with truncation and/or single alanine mutation in HEK-293T cells expressing RXFP1
receptors using a pCRE-galactosidase reporter gene system. Data are expressed as a percentage of maximum H2 relaxin-stimulated cAMP response and are
pooled data from at least three experiments performed in triplicate. Error bars, S.E.
FIGURE 4.Activity of H2 analogues with truncations and/or single alaninemutation on the RXFP2 receptor. A, competition binding results of native H2
relaxin and H2 analogues with truncation and/or single alaninemutation in the presence of a competitive ligand Eu3-labeled INSL3 tested in HEK-293T cells
stably expressing RXFP2 receptors. Data are expressed as a percentage of specific binding and are pooled data from at least three experiments performed in
triplicate. B, cAMP activity of native H2 relaxin and H2 analogueswith truncation and/or single alaninemutation in HEK-293T cells expressing RXFP2 receptors
using apCRE-galactosidase reporter gene system.Data are expressed as apercentageofmaximum INSL3-stimulated cAMP response andarepooleddata from
at least three experiments performed in triplicate. Error bars, S.E.
FIGURE 5.Activity of chimeric H2/INSL5 A-chains on the RXFP1 receptor. A, competition binding results of native H2 relaxin and chimeric H2/I5 A-chain relaxin
analogues in the presence of a competitive ligand Eu3-labeled H2 relaxin tested in HEK-293T cells stably expressing RXFP1 receptors. Data are expressed as a
percentageof specificbindingandarepooleddata fromat least threeexperimentsperformed in triplicate.B, cAMPactivityofnativeH2relaxinandH2analogueswith
truncation and/or single alaninemutation in HEK-293T cells expressing RXFP1 receptors using a pCRE-galactosidase reporter gene system. Data are expressed as a
percentage ofmaximumH2 relaxin-stimulated cAMP response and are pooled data from at least three experiments performed in triplicate. Error bars, S.E.
FIGURE 6.Activity of chimeric H2/INSL5 A-chains on the RXFP2 receptor. A, competition binding results of native H2 relaxin and chimeric H2/I5 A-chain relaxin
analogues in thepresenceof a competitive ligandEu3-labeled INSL3 tested inHEK-293Tcells stablyexpressingRXFP2 receptors.Dataareexpressedasapercentage
of specific bindingandarepooleddata fromat least threeexperimentsperformed in triplicate.B, cAMPactivityof nativeH2 relaxin andH2analogueswith truncation
and/or singlealaninemutation inHEK-293Tcells expressingRXFP2 receptorsusingapCRE-galactosidase reportergenesystem.Dataareexpressedasapercentageof
maximum INSL3-stimulated cAMP response and are pooled data from at least three experiments performed in triplicate. Error bars, S.E.
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for native H2 relaxin (43). From this, it is clear that all elements
of secondary structure, including the three -helical segments
as well as two extended regions forming a small anti-parallel
-sheet, are conserved, evident from stretches of negative and
positive values, respectively. Further support for a retained
overall fold comes from the presence of key long range NOEs
that are hallmarks of the fold, including interchainNOEs across
the -sheet. However, most of these NOEs are weak, and the
lines are generally broader, suggesting an increase in flexibility
of the fold, presumably due to a destabilized hydrophobic core
in the absence of Tyr-3 within the A-chain. This result corre-
lates with the CD data indicating that H2:A(Y3A) exhibited less
helical structure compared with native H2 relaxin (Fig. 7A).
Determination of Collagen Content (Fibrosis)
From the results obtained from both ligand binding and
cAMP activity assays for all H2 relaxin analogues, the peptide
H2:A(4–24)(F23A), which displayed the most selectivity for
RXFP1 over RXFP2, was selected for further functional charac-
terization in both in vitro and in vivo experimental models of
fibrosis.
In Vitro Studies—TGF-1 is a potent stimulator of fibroblast
differentiation and collagen production and was found to sig-
nificantly (p  0.001) promote collagen deposition from BJ3
human dermal fibroblasts (at a dose of 2 ng/ml) over a 72-h
culture period, by60% of thatmeasured in untreated cultures
(Fig. 8). Consistent with H2 relaxin’s previously documented
ability to prevent TGF-1-stimulated collagen deposition from
various fibroblast cultures, regardless of their origin (31–33,
35), co-administration of native H2 relaxin (16.8 nM) to TGF-
1-stimulated BJ3 cells was able to inhibit this aberrant depo-
sition of collagen by 45–50% (p  0.01 versus TGF-1 treat-
ment alone; Fig. 8) over the same time period. Similarly,
co-administration of H2:A(4–24)(F23A) to TGF-1-stimu-
lated cells prevented collagen deposition to the same extent as
nativeH2 relaxin (p 0.01 versusTGF-1 treatment alone; Fig.
8) without affecting basal collagen levels when administered to
unstimulated fibroblasts.
In Vivo Studies—Additionally, in an ISO-induced murine
model of cardiac toxicity and fibrosis, collagen concentration
(percentage of collagen content/dry weight tissue) was signifi-
cantly increased by 2-fold in animals given five daily subcu-
taneous injections of 25 mg/kg ISO before being left for a fur-
ther 12 days for fibrosis progression to accumulate compared
with that measured in untreated control animals (p  0.001
versus control group; Fig. 9). Again, this increase in aberrant
collagen depositionwas significantly prevented in separate sub-
FIGURE 7. Structural studies of H2 relaxin analogues. A, CD spectra result of native H2 relaxin in comparison with H2:A(Y3A). H2 relaxin peptide analogues
for CD were performed in 10 mM phosphate buffer at pH 7.5. B, secondary H chemical shifts of H2 relaxin and H2:A(Y3A). Secondary shifts (i.e. differences
between observed chemical shifts and the random coil shifts) are sensitive indicators of secondary structure. Three distinct regions of negative numbers
corresponding to the three helical segments and two stretches of positive numbers accounting for the two -sheets are seen from both H2 relaxin and
H2:A(Y3A). Although secondary structural elements appear conserved, NOEs appeared to beweak, and lines were generally broader, indicating an increase in
flexibility of the overall fold, which suggests a destabilized structure.
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groups ofmice co-administered with ISO and nativeH2 relaxin
(0.5 mg/kg/day) or ISO and the H2:A(4–24)(F23A) analog (0.5
mg/kg/day) by 45–50% (both p  0.05 versus the ISO alone
group; Fig. 9) to a comparable extent.
DISCUSSION
Since the discovery that the native receptor for H2 relaxin is
the G protein-coupled receptor, RXFP1 (8), increasing efforts
have been made to better understand how H2 relaxin interacts
with not only RXFP1 but also RXFP2, for which it acts as a
ligand. These studies have involved investigations into its pri-
mary mode of action through the B-chain (12) and a secondary
interaction that involves the A-chain of which the intricate
details of the ligand-binding interaction remain unclear (44).
Park et al. (45) has recently performed mutations at the C-ter-
minal helix of theH2 relaxinA-chain in order to understand the
role of this region in binding and activation. They have identi-
fied some residues important for secondary interactions and
suggested that Lys-17 is important for H2-RXFP1 interaction,
whereas Phe-23 andThr-16 are important forH2-RXFP2 inter-
action. However, the nature of H2-RXFP1/RXFP2 interactions
was not clearly realized because no reduction in the affinity for
RXFP1 or RXFP2 was observed upon mutation of Thr-16 or
Lys-17 to alanine residues. Furthermore, Phe-23 within the
A-chain was thought to be interacting directly with the recep-
tor. Thus, the reduction of RXFP2 activity by the Phe-23-mu-
tated analog was speculated to be caused by a residue side chain
effect, whereas the secondary effect relating to structural per-
turbation was not considered. Clearly, furthermutational stud-
ies targeting the entire A-chain were required to understand
the mechanism of secondary interaction, particularly for the
development of RXFP1-selective H2 relaxin agonists or antag-
onists. Hence, we have successfully designed and chemically
synthesized 16 mutants, with all mutations in the A-chain of
the H2 relaxin peptide (Table 1). We demonstrated that no
single amino acid dominates in driving the secondary inter-
action between H2 relaxin and RXFP1, although some con-
tributions were observed from Tyr-3, Leu-20, and Phe-23. In
addition, these same residues predominantly drive the affin-
ity and activity of H2 relaxin at RXFP2. We also propose a
new mechanism in contrast to Park et al. (45), by which the
decreased RXFP2 activity observed from the Phe-23-mu-
tated analog was due to a structural effect rather than spe-
cific side chain-driven influences.
Insights into the Mechanism of Secondary Interaction of
RXFP1 and RXFP2 by H2 Relaxin—Mutational studies for H2
relaxinA-chain residues were conducted on those residues that
had side chains that could affect binding and activation at
RXFP1 and RXFP2. The majority of the H2 relaxin analogues
mutated from the N to C terminus did not have significant
differences in binding and activation at RXFP1. These alanine
substitutions reveal that no individual residues from Lys-9
to Arg-22 are highly critical for RXFP1 activity. However,
H2:A(Y3A) and H2:A(F23A) at the far end of the N and C ter-
mini, respectively, had reduced affinity and potency at RXFP1
and RXFP2 and were able to almost completely abolish RXFP2
binding and activation. This demonstrates that both Tyr-3 and
Phe-23 play an important role in directing RXFP2 specificity,
and by replacing these residues, RXFP2 responseswere severely
compromised, with H2:A(Y3A) giving a slightly greater effect
than H2:A(F23A). In addition, the truncated analog H2:A(4–
24) lacking three residues from the N terminus of the A-chain
displayed reduced activity for RXFP2 but was able to maintain
close to native binding and activation at RXFP1, further con-
firming that the Tyr-3 residue is responsible for the reduction
in RXFP2 responses. Complete ablation of RXFP2 binding and
FIGURE 8. The relative mean  S.E. (error bars) collagen content from
untreated BJ3 fibroblasts and from cells treated with TGF-1 (2 ng/ml)
alone, with H2:A(4–24)(F23A) alone, or with native H2 relaxin (16.8 nM)
or H2:A(4–24)(F23A) (16.8 nM) in TGF-1 (2 ng/ml)-stimulated cells. All
data are expressed as the relative ratio of collagen content measured in the
untreated group, which was expressed as 1, whereas the numbers in paren-
theses represent the number of separate experiments that were conducted
for eachgroup in triplicate. *,p0.001 versus theuntreatedgroup; #,p0.01
versus the TGF-1 alone-treated group.
FIGURE 9. The relative mean  S.E. (error bars) collagen content from
untreated group and frommice treatedwith ISO alone orwith nativeH2
relaxin or H2:A(4–24)(F23A) in ISO-induced myocardial infarction. All
data are expressed as the relative ratio of collagen content measured in the
untreated group, which was expressed as 1, whereas the numbers in paren-
theses represent the number of separate experiments that were conducted
for each group in triplicate. *, p  0.001 versus the untreated group; ∧, p 
0.05 versus the ISO alone-treated group.
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cAMP was achieved with H2:A(4–24)F23, in the absence of
both Tyr-3 and Phe-23 residues, affirming that both residues
are crucial for RXFP2 binding and activation. The third most
important amino acid found in the A-chain was Leu-20, which
is also hydrophobic in nature. It is most likely that the hydro-
phobic interaction between two aromatic residues, along with
the Leu-20 residue inside the core,may stabilize the structure of
H2 relaxin, which might be very important for RXFP2 activity
but not so for RXFP1. Intriguingly, the truncated analog,
H2:A(4–24), showed higher RXFP1 activity compared with
H2:A(Y3A), possibly due to its induced fit conformation for
RXFP1. Finally, having the truncation at theN terminus and the
Phe-23 mutation at the C terminus, we obtained an analog,
H2:A(4–24)(F23A), that exhibited very high activity at RXFP1
but no activity at RXFP2 at nanomolar concentrations. This
result supports our previous hypothesis that “it should be pos-
sible to construct a H2 relaxin analog with high affinity for
RXFP1 but no affinity for RXFP2 by judiciousmutations within
the A-chain of the peptide” (21). As seen from the structural
representation of the H2 relaxin A-chain (Fig. 10), both Tyr-3
and Phe-23 are in close proximity to each other, although one is
present at the N terminus and the other at the C terminus. We
hypothesize that the hydrophobic or - interactions between
these side chains of two aromatic residues are essential for
maintenance of native folding. The removal or mutation of the
Tyr-3 and/or Phe-23 residue(s) may destabilize the structure of
H2 relaxin, causing a loss of affinity and activity. This hypoth-
esis is supported by ourCDandNMRstructural data, where the
H2:A(Y3A) andH2:A(4–24)(F23A) variants exhibited compro-
mised overall fold.
It has been reported that there are very intricate and impor-
tant interactions within both the A- and B-chains of the native
peptide that contribute to RXFP1 and RXFP2 receptor binding
and activation (44). This ranges from a single amino acid with
an important side chain to a series of amino acid residues,
which constitute a domain region necessary to maintain the
correct fold and structure of the peptide. With reference to the
recent INSL3 study (20), we have produced three partial chime-
ras of H2 relaxin and INSL5 in order to find out if a domain
(series of residues) was critical for RXFP1 activity because no
single amino acid in the A-chain was found to be. In stark con-
trast to the INSL3-INSL5 partial chimera, the INSL5-H2 partial
chimera analogues exhibited loss of both affinity and activity.
This ascertains that the secondary binding site requires specific
domains of the H2 relaxin A-chain to be in the correct precise
orientation for subsequent affinity and cAMP responses. The
precise orientation is disrupted, possibly due to the change in
overall structure, which is supported by ourCD andNMR stud-
ies on two analogues we discussed above. Hence, unlike INSL3,
it is not possible to separate the binding and activation events of
H2 relaxin, which confirms our previous hypothesis that
both interactions (binding and activation) at H2-RXFP1 and
H2-RXFP2 are closely related (40). This is again supported by
the fact that the loss of H2-RXFP1/RXFP2 activity is accompa-
nied by a reduction in affinity (Table 2) either with a single
amino acid mutation, single amino acid deletion, or domain
replacement. This is in contrast to the INSL3-RXFP2 system,
where binding and activation are two separate events (35).
Additionally, in contrast to H2 relaxin, the A-chain of structur-
ally related insulin peptide directly engages the key signaling
element of the receptor -subunit (46), and mutations within
the A-chain of insulin directly create marked perturbations to
this interaction (47). The differences between the relative roles
of the A- and B-chains of insulin versus the relaxin family pep-
tide members fundamentally reflect the different classification
of receptors, which ultimately has broad implications for
the evolution and divergence within these respective ligand
families.
The Relaxin Analog H2:A(4–24)(F23A) Is Very Potent in
Vitro and in Vivo—Because native H2 relaxin possesses potent
antifibrotic effects and could potentially be developed as a ther-
apy for fibrotic disorders (2–4, 31–33, 38), it would be interest-
ing to see whether the RXFP1-selective H2 analog, H2:A(4–
24)(F23A), exhibits similar potency to native relaxin both in
vitro and in vivo. The analog was tested in human BJ3 cells in
vitro, which natively express endogenous RXFP1 receptors, and
found to be able to comparably prevent TGF-1-stimulated
collagen deposition.Moreover, when tested in an experimental
mouse model of fibrosis in vivo, the outcomes paralleled those
of the in vitro fibroblast culture study, where H2:A(4–
24)(F23A) was able to significantly and similarly prevent aber-
rant cardiac fibrosis progression to that of native H2 relaxin.
This result also confirms our previous findings that anti-fi-
brotic effects of relaxin are mediated through RXFP1 receptor
(48, 49).
In conclusion, we have identified key A-chain residues span-
ning from the N to C termini that are important for native
structure and function. Our results provide new biochemical
insights into the mechanism of secondary interaction between
H2 relaxin and RXFP1 or RXFP2. Although no single amino
FIGURE 10.Structure of nativeH2 relaxin. The crystal structure of H2 relaxin
(Protein Data Bank code 6RLX) is shown with the side chains of Tyr-3 and
Phe-23 (circled in black) that are present at opposite ends of the relaxin
A-chain in close proximity. The A-chain is shown in red, the B-chain in green,
and the conserved disulfide bridges in blue. The absence of Tyr-3 and/or
Phe-23 contributes to the destabilization of the overall fold of the peptide.
This causes loss of RXFP2 binding and activation because the peptide is
unable to adopt an optimized orientation for binding to the receptor.
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acid in the A-chain was found to be very critical for full RXFP1
binding and activation, Tyr-3, Leu-20, and Phe-23 were found
to be essential for peptide folding and thus for RXFP2 activity.
This led to the creation of an RXFP1-selective analog, H2:A(4–
24)(F23A), that mimics the actions of native H2 relaxin in
diminishing aberrant collagen deposition (anti-fibrotic) in both
in vitro and in vivo experimental models of fibrosis. BecauseH2
relaxin is currently in Phase III clinical trials for the treatment
of acute heart failure, the advantage of having this RXFP1-se-
lective analog will be beneficial to avoid potential undesired
side effects, if any, mediated through RXFP2. Last, this RXFP1
analog will unquestionably serve as a valuable template for the
development of future clinical compounds.
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